Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)

Launched by PFIZER · Apr 3, 2024

Keywords

ClinConnect Summary

The ATTRACT Registry study is looking at how patients with moderate-to-severe atopic dermatitis (a type of eczema) are treated with a medication called abrocitinib over the course of 12 months. The goal is to understand how effective this treatment is in the real world and to gather information about the patients who are being treated. This study is currently recruiting participants aged 12 and older who have been diagnosed with moderate-to-severe atopic dermatitis and for whom their doctor has decided to start them on abrocitinib.

To join the study, participants must not have used abrocitinib before and should not be involved in any other research studies that include experimental medications. Those who take part will be monitored over the year to see how well the treatment works and how it impacts their daily lives. This is a great opportunity for patients to contribute to important research that can help others with similar skin conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
• • 1. Patients aged ≥12 years
• • 2. Patients with confirmed diagnosis of moderate-to-severe AD as assessed by the physician
• • 3. Patients for whom the physician's decision has been made to newly prescribe abrocitinib in usual clinical practice conditions
• • 4. Evidence of a personally signed and dated informed consent/assent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study
• Exclusion Criteria:
• Patients meeting any of the following criteria will not be included in the study:
• • 1. Any prior use of abrocitinib
• • 2. Simultaneous participation in a study that includes administration of any investigational drug or procedure